CRIS Current Research Information System

LUGARESI, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 15.083
NA - Nord America 11.766
EU - Europa 8.924
SA - Sud America 1.352
AF - Africa 529
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 5
Totale 37.681
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.609
VN - Vietnam 5.016
SG - Singapore 3.629
CN - Cina 3.396
GB - Regno Unito 2.550
IT - Italia 1.855
DE - Germania 1.536
HK - Hong Kong 1.069
BR - Brasile 1.010
FR - Francia 789
IN - India 728
RU - Federazione Russa 559
SE - Svezia 364
IE - Irlanda 268
KR - Corea 265
ZA - Sudafrica 260
JP - Giappone 248
EE - Estonia 185
NL - Olanda 179
FI - Finlandia 156
UA - Ucraina 136
AR - Argentina 127
ID - Indonesia 108
BD - Bangladesh 95
TR - Turchia 75
TG - Togo 74
EC - Ecuador 72
CA - Canada 66
AT - Austria 65
PH - Filippine 63
IQ - Iraq 59
MX - Messico 55
CI - Costa d'Avorio 53
CH - Svizzera 40
CO - Colombia 40
ES - Italia 38
PL - Polonia 38
IR - Iran 36
PK - Pakistan 35
JO - Giordania 34
TH - Thailandia 32
UZ - Uzbekistan 31
GR - Grecia 30
SA - Arabia Saudita 28
CL - Cile 27
PY - Paraguay 24
BG - Bulgaria 23
BE - Belgio 22
SC - Seychelles 21
VE - Venezuela 21
EG - Egitto 20
MY - Malesia 20
AU - Australia 17
MA - Marocco 16
NG - Nigeria 15
TW - Taiwan 15
DO - Repubblica Dominicana 14
DZ - Algeria 14
HR - Croazia 14
KE - Kenya 14
PE - Perù 14
AZ - Azerbaigian 13
KZ - Kazakistan 12
LB - Libano 11
UY - Uruguay 11
CZ - Repubblica Ceca 10
JM - Giamaica 10
NP - Nepal 10
RO - Romania 10
IL - Israele 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
RS - Serbia 8
LT - Lituania 7
PS - Palestinian Territory 7
AL - Albania 6
BO - Bolivia 6
GA - Gabon 6
ET - Etiopia 5
BH - Bahrain 4
DK - Danimarca 4
GE - Georgia 4
NZ - Nuova Zelanda 4
OM - Oman 4
PT - Portogallo 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
AM - Armenia 3
CR - Costa Rica 3
CY - Cipro 3
GH - Ghana 3
LV - Lettonia 3
MT - Malta 3
SI - Slovenia 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
EU - Europa 2
Totale 37.636
Salva come PNG Salva come JPEG
Città #
Singapore 2.353
Southend 2.335
Fairfield 1.402
Ho Chi Minh City 1.314
Hanoi 1.131
Ashburn 1.115
Hong Kong 1.039
Woodbridge 630
Seattle 597
Wilmington 597
Houston 596
Hefei 573
Princeton 534
Beijing 519
Ann Arbor 505
Cambridge 496
Dong Ket 438
San Jose 435
Santa Clara 435
Boardman 424
Lauterbourg 423
Chandler 351
Dublin 259
Nanjing 246
Bologna 238
Seoul 237
Westminster 234
Tokyo 229
Berlin 197
Council Bluffs 194
Padova 191
Milan 178
Frankfurt am Main 154
Haiphong 148
Los Angeles 142
Da Nang 141
Redondo Beach 128
Dallas 124
Saint Petersburg 111
Buffalo 109
San Diego 102
Helsinki 101
Jinan 94
Biên Hòa 90
Medford 89
Rome 86
Quận Bình Thạnh 84
Shenyang 84
São Paulo 83
Ha Long 81
Dearborn 76
Lomé 74
Guangzhou 72
Hải Dương 72
Can Tho 71
Hebei 71
Bremen 69
Nanchang 68
Changsha 66
Nuremberg 65
Ninh Bình 62
Redmond 62
Bengaluru 61
Thái Nguyên 59
Shanghai 57
Tianjin 53
Abidjan 52
Moscow 52
Munich 51
Turin 49
New York 47
Des Moines 46
Jakarta 44
Zhengzhou 44
Falls Church 42
Vũng Tàu 42
Norwalk 41
Bắc Giang 40
Bắc Ninh 40
Rio de Janeiro 40
Chicago 38
Jiaxing 37
Lappeenranta 37
Florence 36
Amman 33
Hangzhou 33
Phủ Lý 33
Vinh 33
London 31
Quận Một 30
Xi'an 30
Ningbo 27
Quận Phú Nhuận 27
Taizhou 27
Tashkent 27
Thái Bình 27
Toronto 27
Vienna 26
Bến Tre 25
Haikou 25
Totale 24.693
Salva come PNG Salva come JPEG
Nome #
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study 2.798
Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis 465
Distonia faringea parossistica non dolorosa: un esordio atipico di sclerosi multipla. 429
Circadian Activity Rhythm in Early Relapsing-Remitting Multiple Sclerosis 233
Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis 223
The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy. 213
Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure 210
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study 202
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 193
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: A prospective study 187
Assessing robustness of quantitative susceptibility-based MRI radiomic features in patients with multiple sclerosis 186
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship 177
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression 172
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31 172
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 171
A Pilot Study of 24-h Motor Activity Patterns in Multiple Sclerosis: Pre-Planned Follow-Up at 2 Years 169
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 167
eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54 166
The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. 165
Dissipation of Motor Sleep Inertia and Motor Wake Inertia in Early Relapsing–Remitting Multiple Sclerosis 164
Multiparametric MRI dataset for susceptibility-based radiomic feature extraction and analysis 163
The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system's preparedness 162
When 'good' is not good enough: a retrospective Rasch analysis study of the Berg Balance Scale for persons with Multiple Sclerosis 158
Sleep-related disorders and their relationship with MRI findings in multiple sclerosis 156
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 155
Anxiety and depression in multiple sclerosis patients around diagnosis 151
Decidere la maternità. Un ausilio per le donne con SM 151
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis 147
Use of herbal remedies by multiple sclerosis patients: a nation-wide survey in Italy 147
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 147
BREMSO: A simple score to predict early the natural course of multiple sclerosis 146
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study 145
Development of a short version of MSQOL-54 using factor analysis and item response theory 145
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 144
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 141
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 139
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 139
Sapere Migliora : informazioni sulla SM per la persona neodiagnosticata 137
Beyond disease: Happiness, goals, and meanings among persons with multiple sclerosis and their caregivers 137
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 135
Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry 134
Burden and resources in caregivers of people with multiple sclerosis: A qualitative study 133
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis 132
Advance Care Planning in Neurodegenerative Disorders: A Scoping Review 132
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study 131
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom 131
The brief international cognitive assessment for multiple sclerosis (bicams): normative values in the Italian population. 131
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience 130
Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype 130
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells 129
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 128
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 127
Comparative efficacy of switching to natalizumab in active multiple sclerosis 127
Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments 127
Home-based palliative approach for people with severe multiple sclerosis and their carers: Study protocol for a randomized controlled trial 127
A computational platform for MALDI-TOF mass spectrometry data: Application to serum and plasma samples 127
Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. 126
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 126
Disability accrual in primary and secondary progressive multiple sclerosis 125
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 125
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 125
Predictors of disability worsening in clinically isolated syndrome. 124
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis 123
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial 123
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 121
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 121
The Italian multiple sclerosis register 121
Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial 121
The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. 120
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 119
Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention. 119
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study 119
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. 118
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 117
Evaluating dalfampridine for the treatment of relapsing-remitting multiple sclerosis: does it add to the treatment armamentarium? 117
Applying multidimensional computerized adaptive testing to the MSQOL-54: a simulation study 116
F response in vascular and degenerative upper motor neuron lesions 116
A comparison of the Brief International Cognitive Assessment for Multiple Sclerosis and a brief repeatable battery in multiple sclerosis patients. 115
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 115
Editorial: Aging in multiple sclerosis: from childhood to old age, in women and men 113
A comparison of the brief International cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. 113
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy 113
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories 113
Risk of secondary progressive multiple sclerosis: A longitudinal study 113
Conversion to secondary progressive multiple sclerosis: Patient awareness and needs. Results from an online survey in Italy and Germany 113
Women and multiple sclerosis: From gender medicine to precision medicine 112
Fingolimod after natalizumab and the risk of short-term relapse 112
Cognitive dysfunction in patients with relapsing-remitting Multiple Sclerosis 111
IL-4 in vitro production is upregulated in Alzheimer's disease patients treated with acetylcholinesterase inhibitors 111
Cleavage of cystatin C is not associated with multiple sclerosis 111
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 110
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 110
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. 110
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 109
Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study. 109
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study 109
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 109
Ponesimod for the treatment of relapsing multiple sclerosis 109
Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA) 108
Risk of relapse phenotype recurrence in multiple sclerosis. 108
Totale 16.981
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.862
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.862
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.112 0 0 0 0 0 0 0 0 0 149 115 848
2021/20223.919 314 350 207 199 448 238 119 372 146 219 517 790
2022/20233.063 357 456 152 395 139 161 166 165 502 170 221 179
2023/20241.130 91 157 86 85 98 101 63 112 55 69 94 119
2024/20255.937 206 1.062 613 452 792 397 361 166 152 168 310 1.258
2025/202614.614 3.410 1.521 1.592 1.190 1.139 671 1.315 612 2.313 851 0 0
Totale 38.827